Peptides DB
Research-centric peptide and protocol reference hub

Leuprorelin record · updated 6h ago

Healing & recoveryGrade A · human clinicalResearch use only
All 28 studiesJump to the evidenceCompare
What is Leuprorelin used for?

Leuprorelin is a synthetic analog of gonadotropin-releasing hormone (GnRH) that primarily acts as a GnRH agonist. Its mechanism of action involves the downregulation of gonadotropin secretion from the pituitary gland, which leads to decreased levels of sex hormones such as testosterone and estrogen. This property makes leuprorelin particularly useful in the treatment of hormone-sensitive conditions, including prostate cancer and precocious puberty.

How it works: GnRH agonist

Primarily researched for · Healing & recoveryRoute · Subcutaneous injection

Development stage

where Leuprorelin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 65 registered trials. It describes the research record, not a recommendation.

Identity
NameLeuprorelin
Chain length—
Molecular weight1,209.4 Da
FormulaC59H84N16O12
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 657181. No verified residue count for this compound.

Pharmacology
MechanismGnRH agonist
RouteSubcutaneous injection
Half-life~3 hours
Time to peak1–2 hours
Duration1 month
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 19, 2026. How this works →
Research stats
Total studies28
Human / animal / cellular19 / 3 / 0
Highest trial phasePhase 4
Years covered2021–2026
Latest study2d ago
Publication history
20212026
Research funding
140 NIH projects · $32.6M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports1,137
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

28 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
TakeawayNot reported in abstract.
Human2026Title only0.10
Transdermal Estradiol Patches in Locally Advanced Prostate Cancer.
TakeawayNot reported in abstract.
—2026Title only0.10
Meningioma enlargement associated with luteinizing hormone-releasing hormone agonist therapy: two cases and supporting in vitro evidence.
FindingNot reported in abstract.
Human2023Full text read0.70
H&E to recurrence score: A step forward, but not yet a substitute for genomic testing.
FindingAUC of 0.898 for identifying recurrence score ≥26.
review2026Full text read0.80
Diagnosis of metastatic prostate cancer by supraclavicular lymph node excision in a patient with persistent macroscopic hematuria: A case report.
TakeawayConventional diagnostic methods may miss metastatic prostate cancer; comprehensive approaches, including advanced imaging, are crucial.
Human2026Full text read0.70
Peptide Therapeutics for Solid Tumors: Functional Classes, AI-Enhanced Discovery and Clinical Advances.
TakeawayPeptide therapeutics show potential in treating solid tumors, with AI enhancing their design and discovery.
review2026Full text read0.80
Novel GnRH analogue decorated paclitaxel and CQDs co-loaded theranostic zein nanoparticles for treatment of breast cancer: Formulation optimization, in vitro and in vivo evaluation.
FindingParticle size of 154.23 ± 7.51 nm.
Animal2026Full text read0.70
Impact of leuprolide and goserelin on androgen suppression and adverse events in patients with prostate cancer.
FindingNot reported in abstract.
Human2026Full text read0.80
French multicentre randomised phase III trial evaluating the efficacy and safety of vaginal radiofrequency in the management of vulvovaginal atrophy and dryness in patients treated for breast cancer (RF-Vaginale): trial protocol.
FindingNot reported in abstract.
review2026Full text read0.70
Clinical and Genetic Spectrum of <i>ATP1A3</i>-Related Disorders: A Multicenter Cross-Sectional Study.
Finding41 patients with ATP1A3 variants included.
Human2023Full text read0.80
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
FindingHR 0.944, 95% CI 0.486-1.8392 for DFS between ≥3 years and 2 years.
Human2021Full text read0.80
Revisiting the Association of Central Precocious Puberty with Neurovisceral Diseases owing to a Girl with Niemann-Pick Disease Type C.
FindingHeight velocity was 0.4 SDS at the first year of follow-up.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Leuprorelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Leuprorelin is discussed should be drawn from it.